Leukine market seen growing on cancer care demand
The Business Research Company says the global Leukine market is set to expand through 2026 as cancer treatments, supportive care and immune recovery needs rise. North America held the largest share in 2025, while Asia-Pacific is projected to grow fastest.
Why it matters: - Leukine is used to help patients rebuild white blood cells after chemotherapy or bone marrow transplants, making it part of supportive cancer care. - Rising cancer survival rates and a larger population needing immune support are expanding demand for biologic supportive medicines. - The market outlook matters because leukemia and other cancers can leave patients vulnerable to infection during recovery.
What happened: - The Business Research Company released its Leukine Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report says the Leukine market is positioned for notable growth through 2026. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - A free sample is available through the company’s sample request page. - The full report is available through the company’s report page.
The details: - Leukine, or sargramostim, is designed to boost white blood cell production after chemotherapy or bone marrow transplants. - Leukine stimulates granulocytes and macrophages, which help fight infections in patients with weakened immune systems. - Past market growth was driven by expanded chemotherapy use, progress in cytokine therapy, more oncology and hematology treatment centers, improved cancer survival rates and stronger supportive care protocols. - Forecast growth is tied to greater demand for immune support after chemotherapy, more personalized oncology treatment, higher investment in immunostimulatory therapies, more attention to reducing treatment complications and wider adoption of biologic supportive medicines. - Emerging trends include broader use of hematopoietic growth factors in oncology, more focus on preventing infections in immunocompromised patients and optimization of injectable biologic formulations. - The report says leukemia incidence is a major growth driver for Leukine demand. - The American Cancer Society reported 62,770 new leukemia cases in the U.S. in 2024, up from 59,610 in 2023. - North America held the largest share of the Leukine market in 2025. - Asia-Pacific is expected to post the fastest growth during the forecast period.
Between the lines: - The report frames Leukine demand as part of a broader shift toward post-treatment recovery, not just active cancer treatment. - Growth appears linked to both more patients and more intensive supportive-care standards across oncology. - The emphasis on injectable biologics and immunostimulatory therapies suggests the market is moving toward more specialized hospital and clinic use.
What's next: - The market is expected to keep expanding as cancer care protocols continue to prioritize infection prevention and immune recovery. - Asia-Pacific growth could narrow the gap with North America if supportive-care adoption continues to accelerate. - The company’s 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, key technology analysis and future trend analysis. - Additional company contact information and social links were included with the release, including LinkedIn, Facebook and X.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Let's Party! Latin America
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.